These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

694 related items for PubMed ID: 22211581

  • 1. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab.
    Torii H, Sato N, Yoshinari T, Nakagawa H, Japanese Infliximab Study Investigators.
    J Dermatol; 2012 Mar; 39(3):253-9. PubMed ID: 22211581
    [Abstract] [Full Text] [Related]

  • 2. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [Abstract] [Full Text] [Related]

  • 3. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H, Nakagawa H, Japanese Infliximab Study investigators.
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [Abstract] [Full Text] [Related]

  • 4. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [Abstract] [Full Text] [Related]

  • 5. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.
    Dermatology; 2008 Aug; 216(3):260-70. PubMed ID: 18187944
    [Abstract] [Full Text] [Related]

  • 6. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas AD.
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [Abstract] [Full Text] [Related]

  • 7. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab.
    Reich K, Griffiths CE.
    Arch Dermatol Res; 2008 Nov; 300(10):537-44. PubMed ID: 18784934
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K.
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [Abstract] [Full Text] [Related]

  • 9. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE.
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [Abstract] [Full Text] [Related]

  • 10. An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.
    Mrowietz U, Kragballe K, Reich K, Griffiths CE, Gu Y, Wang Y, Rozzo SJ.
    Br J Dermatol; 2013 Feb; 168(2):374-80. PubMed ID: 22880843
    [Abstract] [Full Text] [Related]

  • 11. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI, PEARL investigators.
    J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
    [Abstract] [Full Text] [Related]

  • 12. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
    Puig L.
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA.
    Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
    [Abstract] [Full Text] [Related]

  • 14. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, Morel P, Dubertret L, Bachelez H.
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [Abstract] [Full Text] [Related]

  • 15. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
    Petridis A, Panagakis P, Moustou E, Vergou T, Kallidis P, Mandekou-Lefaki I, Chaidemenos G, Sotiriadis D, Alexopoulou G, Haratsis Y, Antoniou C.
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
    [Abstract] [Full Text] [Related]

  • 16. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
    Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A.
    Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
    [Abstract] [Full Text] [Related]

  • 17. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD.
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [Abstract] [Full Text] [Related]

  • 18. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.
    Shear NH, Hartmann M, Toledo-Bahena ME, Gilbert M, Katsambas A, Yao R, Popmihajlov Z.
    Qual Life Res; 2016 Aug; 25(8):2031-40. PubMed ID: 26869477
    [Abstract] [Full Text] [Related]

  • 19. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN.
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [Abstract] [Full Text] [Related]

  • 20. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG.
    Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.